-+ 0.00%
-+ 0.00%
-+ 0.00%

Silo Pharma files provisional patent for ibogaine-based traumatic brain injury treatment

PUBT·05/07/2026 12:12:59
Listen to the news
Silo Pharma files provisional patent for ibogaine-based traumatic brain injury treatment
  • Silo Pharma filed a US provisional patent application covering ibogaine-based compositions and methods to treat traumatic brain injury, with claims extending to PTSD and related neuropsychiatric conditions.
  • Move targets a market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury.
  • Company pointed to published clinical and neuroimaging findings that reported symptom improvements and measurable brain-structure changes following a single ibogaine-based treatment.
  • Traumatic brain injury therapeutics market projected to reach USD 6 billion by 2032, according to company estimates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070805PRIMZONEFULLFEED9715099) on May 07, 2026, and is solely responsible for the information contained therein.